RecruitingPhase 1NCT05998408
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
Studying Idiopathic aplastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Principal Investigator
- Emma M Groarke, M.D., MDNational Heart, Lung, and Blood Institute (NHLBI)
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 145 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2024 – 2030
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05998408 on ClinicalTrials.govOther trials for Idiopathic aplastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05126849Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After ImmunosuppressionAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05012111Natural History of Acquired and Inherited Bone Marrow Failure SyndromesNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE1, PHASE2NCT03500731Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailurePaul Szabolcs